No Data
No Data
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $300 to $430.
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad Laboratories, Inc. Class A (BIO) is currently at $298.34, up $16.08 or 5.7% --Would be highest close since May 15, 2024, when it closed at $300.97 --On pace for largest percent increase sinc
$842.7 Million SDS Poly Acrylamide Gel Electrophoresis Market Forecast, 2030 - Featuring Profiles of 13 Companies Including Abcam, Bio-Rad Laboratories, GE Healthcare, and Thermo Fisher Scientific
There's Reason For Concern Over Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Price
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Life Sciences industry in the United States, you could be forgiven for feeling indifferent about Bio-Rad Laboratories, Inc.'s (NY
Bio-Rad Laboratories(BIO.US) Officer Sells US$104.02K in Common Stock
$Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael sold 369 shares of common stock on Jun 13, 2024 at an average price of $281.9064 for a total value of $104.02K.Source: Announcement What is state